Switching to iptacopan improves anemia and symptoms in PNH patients, indicating a valuable treatment option.
Switching to iptacopan led to rapid and durable improvement in anemia and symptoms, supporting proximal complement inhibition as a valuable option for PNH patients inadequately controlled with C5 inhibitors.
No takes yet. Share an insight, caveat, or question.
Ogiya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: